Daylight photodynamic therapy for actinic keratoses: A randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate

British Journal of Dermatology

Volumn 171, Issue 5, 2014, Pages 1172-1180

  Neittaanmaki Perttu N ^a   Karppinen, T T ^b   Gronroos M ^b   Tani, T T ^b   Snellman, E ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Rheumatology Clinic   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; PHOTOSENSITIZING AGENT; PROTEIN P53; BF-200 ALA; METHYL 5-AMINOLEVULINATE;

ACTINIC KERATOSIS; ADULT; ARTICLE; CLINICAL ARTICLE; DAYLIGHT PHOTODYNAMIC THERAPY; DRUG CLEARANCE; DRUG EFFICACY; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NANOEMULSION; PAIN; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; AGED; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FACIAL DERMATOSES; KERATOSIS, ACTINIC; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SCALP DERMATOSES; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; DOUBLE-BLIND METHOD; FACIAL DERMATOSES; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; SCALP DERMATOSES; TREATMENT OUTCOME;

EID: 84911386090     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13326     Document Type: Article

References (27)

1. Callen JP, Bickers DR, Moy RL,. Actinic keratoses. J Am Acad Dermatol 1997; 36: 650-3.
2. Benjamin CL, Melnikova VO, Ananthaswamy HN,. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008; 624: 265-82.
3. Tsatsou F, Trakatelli M, Patsatsi A, et al,. Extrinsic aging: UV-mediated skin carcinogenesis. Dermatoendocrinol 2012; 4: 285-97.
4. Braakhuis BJ, Tabor MP, Kummer JA, et al,. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-30.
5. Braathen LR, Morton CA, Basset-Seguin N, et al,. Photodynamic therapy for skin field cancerization: an international consensus. J Eur Acad Dermatol Venereol 2012; 26: 1063-6.
6. Morton CA, Szeimies RM, Sidoroff A, Braathen LR,. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications-actinic keratosis, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536-44.
7. Morton CA, Szeimies RM, Sidoroff A, Braathen LR,. European guidelines for topical photodynamic therapy part 2: emerging indications-field cancerization, photorejuvenation and inflammatory/infective dermatoses. J Eur Acad Dermatol Venereol 2013; 27: 672-9.
8. Ericson MB, Wennberg AM, Larkö O,. Review of photodynamic therapy in actinic keratosis and basal cell carcinoma. Ther Clin Risk Manag 2008; 4: 1-9.
9. Wiegell SR, Haederstal M, Philipsen PA, et al,. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 2008; 158: 740-6.
10. O'Connor AE, Gallagher WM, Byrne AT,. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 2009; 85: 1053-74.
11. Maisch T, Santarelli F, Schreml S, et al,. Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Exp Dermatol 2010; 19: 302-5.
12. Fitzpatrick TB,. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869-71.
13. Olsen A, Abernethy I, Kulp-Shorten C, et al,. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738-43.
14. Maltusch A, Röwert-Huber J, Matthies C, et al,. Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis. J Dtsch Dermatol Ges 2011; 9: 1011-17.
15. Cockerell CJ,. Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis'). J Am Acad Dermatol 2000; 42: 11-17.
16. Einspahr J, Alberts DS, Aickin M, et al,. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin. Cancer Epidemiol Biomarkers Prev 1997; 6: 583-7.
17. Aron M, Luthringer DJ, McKenney JK, et al,. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol 2013; 37: 1815-23.
18. Wiegell SR, Haederstal M, Eriksen P, et al,. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol 2009; 160: 1308-14.
19. Wiegell SR, Fabricius S, Stender M, et al,. A randomized, multicentre study of directed daylight exposure times of 1 vs. 2 h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol 2011; 164: 1083-90.
20. Wiegell SR, Wulf HC, Szeimies RM, et al,. Daylight photodynamic therapy for actinic keratosis: an international consensus. J Eur Acad Dermatol Venereol 2012; 26: 673-9.
21. Wiegell SR, Fabricius S, Gniadecka M, et al,. Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study. Br J Dermatol 2012; 166: 1327-32.
22. Wiegell SR, Fabricius S, Heydenreich J, et al,. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographic locations. Br J Dermatol 2013; 168: 186-91.
23. Dirschka T, Radny P, Dominicus R, et al,. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166: 137-46.
24. Tarsted M, Rosdahl I, Berne B, et al,. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005; 85: 424-8.
25. Bagazgoitia L, Cuevas Santos J, Juarranz À, Jaén P,. Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 2011; 165: 144-51.
26. Szeimies RM, Torezan L, Niwa A, et al,. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150-9.
27. Moloney FJ, Collins P,. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 2007; 157: 87-91.